RxDoctor Payments Data

Paige Harrison, DO

Physical Medicine & Rehabilitation · Baltimore, MDNPI 1164809646

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 48.2% of the total.

$1,759in general payments, 2019–2025

Across 80 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$848
  • Merz Pharmaceuticals, LLC$661
  • Ipsen Biopharmaceuticals, Inc$39
  • Revance Therapeutics, Inc.$37
  • Nevro Corp.$32
  • Averitas Pharma Inc.$29
  • plus $113 from 6 others

What the payments were for

  • Food & beverage$1,759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,759 in reported general payments places this provider in the 80th percentile of 202 physical medicine & rehabilitation providers in Maryland.

See all physical medicine & rehabilitation providers in Maryland

Medicare billing

Part B allowed, 2024
$101,389
Medicare patients
195
Services billed
4,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl64$41,791
Oxycodone Hcl681$13,382
Xtampza ErOxycodone Myristate11$7,769
Pregabalin213$5,627
Gabapentin216$3,554
Tramadol Hcl172$2,135
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen68$1,710
Naloxone Hcl18$1,445
Tizanidine Hcl77$1,363
Morphine Sulfate ErMorphine Sulfate52$1,270
Hydromorphone Hcl35$1,225
Baclofen50$936
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen47$932
Cyclobenzaprine Hcl46$531
Morphine Sulfate14$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$19$7,76911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 202 physical medicine & rehabilitation providers in Maryland.

Other physical medicine & rehabilitation in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →